Akiba Takashi
Department of Blood Purification, Tokyo Women's Medical University.
Clin Calcium. 2009 Apr;19(4):537-44.
Introduction of CKD-MBD changed clinical attitudes for the therapy of metabolic bone disease in maintenance dialysis therapy as the systemic diseases of calcium phosphate metabolism. We present the variation of target serum calcium, phosphate and parathyroid hormone levels in the guidelines of US and European countries. We also review the management of drug use especially concomitant active vitamin D metabolites and calcium carbonate to cinacalcet prescription.
慢性肾脏病-矿物质和骨异常(CKD-MBD)的引入改变了维持性透析治疗中作为钙磷代谢全身性疾病的代谢性骨病治疗的临床观念。我们介绍了美国和欧洲国家指南中目标血清钙、磷和甲状旁腺激素水平的变化。我们还回顾了药物使用的管理,尤其是活性维生素D代谢物与碳酸钙联合使用至西那卡塞处方的情况。